Zealand Pharma A/S (NASDAQ:ZEAL) is reporting third quarter financial results on Thursday 12th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ZEAL is expected to report 3Q20 loss of $ 0.89 per share from revenue of $ 11.35 million.
For the full year, analysts anticipate top line of $ 64.19 million, while looking forward to loss of $ 2.75 per share bottom line.
Stock Performance
Shares of Zealand Pharma A/S traded up $ 0.44 or 1.17 percent on Wednesday, reaching $ 38.05 with volume of 3.20 thousand shares. Zealand Pharma A/S has traded high as $ 38.36 and has cracked $ 37.76 on the downward trend
The closing price of $ 38.05, representing a 70.95 % increase from the 52 week low of $ 22.00 and a 15.67 % decrease over the 52 week high of $ 44.60.
The company has a market capital of $ 1.49 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Overweight rating, with $ 45.00 target price.
Conference Call
Zealand Pharma A/S will be hosting a conference call at 10:00 AM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, +1 631 510 7495 (United States), when prompted, enter passcode 1296466 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.zealandpharma.com
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua.
